Fibrosis, Liver Clinical Trial
Official title:
Impact of Chlordecone Exposure on Evolution of Fibrosis to Cirrhosis in Chronic Hepatitis C, B or Alcoholic, in Guadeloupe.
Chlordecone is known to induce liver damage in rat and mice but no data exists in human being. However chlordecone was used until 1993 in French West Indies for banana fields, it is important to test what damage can be induced now, for patients exposed. We should consider chlordecone as a potential cofactor of liver fibrosis. So we have chosen to compare two populations of chronic hepatitis B, C or alcoholic, with cirrhosis or without fibrosis due to active hepatitis, who had been exposed to chlordecone.
Actually, there is no data concerning the impact of chlordecone on the evolution of fibrosis to cirrhosis in chronic hepatitis whereas many studies have been reported liver damage in mice. The goal of this study is to know if co-exposition to chlordecone can induce evolution to cirrhosis in chronic hepatitis due to alcohol or viral hepatitis. At first, we will assess a group of patients with chronic hepatitis B, C or due to alcohol without fibrosis. And they will be compared to patients with cirrhosis exposed to chlordecone too. Patients will be included in 2 hospital centers. All these patients should have an active liver disease. The activity will be defined by histology or elevated transaminases (>2N), fibrosis will be defined by histology or an association of fibroscan and biological markers. Exposition to chlordecone will be evaluated by a blood chlordecone measure for every patient. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
| Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
| Active, not recruiting |
NCT05473806 -
Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
|
Phase 4 | |
| Not yet recruiting |
NCT06463223 -
HIBOC = Hepatic Imaging Biomarkers in Obese Children
|
||
| Not yet recruiting |
NCT03222167 -
Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b
|
Phase 3 | |
| Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
| Not yet recruiting |
NCT05567614 -
Platelets Indices and Its Role to Predict Liver Fibrosis in Patients With Chronic Hepatitis B Infection
|
||
| Active, not recruiting |
NCT05402371 -
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
|
Phase 2 | |
| Recruiting |
NCT02569567 -
Comparison of Smart-Shear Wave Elastography and Transient Elastography
|
N/A | |
| Recruiting |
NCT05855031 -
The Liver Care Trial
|
N/A | |
| Completed |
NCT04493346 -
Shear Wave Elastography
|
||
| Completed |
NCT04380493 -
The Use of the Transient Elastography Paediatric Probe, Compared to the M Probe, Indirect Biomarkers and Histology
|
||
| Active, not recruiting |
NCT06315361 -
DIAbetes and NAFLD
|
||
| Not yet recruiting |
NCT03492879 -
Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity
|
N/A | |
| Not yet recruiting |
NCT06366425 -
Screening for Chronic Liver Diseases in General Population
|
N/A | |
| Recruiting |
NCT04442334 -
The European NAFLD Registry
|
||
| Recruiting |
NCT05692024 -
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
|
Phase 1/Phase 2 | |
| Completed |
NCT03659058 -
Impact of Ursodeoxycholic Acid, Silymarin, Antioxidants and Colchicine on Fibrosis Regression in HCV After SVR
|
N/A | |
| Recruiting |
NCT05218538 -
Liver Cirrhosis Diagnosis Prioritizing Algorithm Based on Electronic Health Records.
|
||
| Recruiting |
NCT06248580 -
Find HDV and Determine Its Status in Turkey
|